The Center for Maternal-Fetal Precision Medicine will host an online international conference on Alpha Thalassemia Major (ATM), which was once considered universally fatal in utero. If left untreated, a fetus with ATM will develop severe anemia and hydrops and will die before or shortly after birth. However, recent evidence from patient registries has demonstrated that when ATM is diagnosed early in pregnancy, in utero transfusions (IUT) can reverse hydrops and enable survival with good neurological outcomes.
- Demonstrate the impact of prenatal therapy on postnatal and long-term outcomes of Alpha Thalassemia Major (ATM)
- Understand best practices for prenatal and postnatal treatment of ATM
- Bring together families affected by ATM to share their diagnosis and treatment journeys
- Build international connections among scientists, medical professionals, and patient advocates to advance treatments for ATM worldwide
The agenda is available below and can also be downloaded as a PDF.